Microbes Saving Lives and Reducing Suffering

Microbial Biotechnology, Journal Year: 2025, Volume and Issue: 18(1)

Published: Jan. 1, 2025

Language: Английский

---

Circular RNAs in cancer

MedComm, Journal Year: 2025, Volume and Issue: 6(2)

Published: Feb. 1, 2025

Abstract Circular RNA (circRNA), a subtype of noncoding RNA, has emerged as significant focus in research due to its distinctive covalently closed loop structure. CircRNAs play pivotal roles diverse physiological and pathological processes, functioning through mechanisms such miRNAs or proteins sponging, regulation splicing gene expression, serving translation templates, particularly the context various cancers. The hallmarks cancer comprise functional capabilities acquired during carcinogenesis tumor progression, providing conceptual framework that elucidates nature malignant transformation. Although numerous studies have elucidated role circRNAs cancers, their functions development chemoradiotherapy resistance remain unexplored clinical applications circRNA‐based translational therapeutics are still infancy. This review provides comprehensive overview circRNAs, covering biogenesis, unique characteristics, functions, turnover mechanisms. We also summarize involvement relevance biomarkers therapeutic targets, especially thyroid (TC). Considering potential fascination therapeutics, “Ying‐Yang” dynamic regulations TC warrant vastly dedicated investigations.

Language: Английский

---

Identification of intratumoral microbiome-driven immune modulation and therapeutic implications in diffuse large B-cell lymphoma

Cancer Immunology Immunotherapy, Journal Year: 2025, Volume and Issue: 74(4)

Published: March 3, 2025

Diffuse large B-cell lymphoma (DLBCL) is the most common subtype of non-Hodgkin lymphoma, with significant clinical heterogeneity. Recent studies suggest that intratumoral microbiome may influence tumor microenvironment, affecting patient prognosis and therapeutic responses. This study aims to identify microbiome-related subtypes in DLBCL assess their impact on prognosis, immune infiltration, sensitivity. Transcriptomic data from 48 patients were obtained public databases. Consensus clustering was used classify into distinct subtypes. Functional enrichment analysis, infiltration assessments, single-cell RNA sequencing performed explore biological characteristics these Drug sensitivity predictions made using OncoPredict tool. Hub genes' expression function validated inferred cell lines independent cohorts DLBCL. Two identified. Patients Cluster 1 exhibited significantly better overall survival (P < 0.05), higher regulatory T cells M0 macrophages compared 2, which associated poorer outcomes. analysis revealed genes involved pathways, including cytokine-cytokine receptor interactions chemokine signaling, suggesting enhanced anti-tumor In contrast, 2 enriched immunosuppressive contributing a less favorable prognosis. Single-cell heterogeneity populations within microenvironment. B notable heterogeneity, as indicated by stemness differentiation potential scoring. Intercellular communication demonstrated played key role interactions, differences observed MIF signaling between subgroups. Pseudo-time further trajectories cells, highlighting across different environments. Metabolic pathway showed average levels metabolic pathways among subgroups, functional specialization. Furthermore, interaction core microbiome-driven differentially expressed identified nine (GSTM5, LURAP1, LINC02802, MAB21L3, C2CD4D, MMEL1, TSPAN2, CITED4), found play critical roles influenced microbiome. MMEL1 CITED4 important biologically classification. demonstrates prognostic significance DLBCL, identifying activity, The findings provide insights focusing dynamics. These results lay foundation for microbiome-based biomarkers personalized treatment approaches, ultimately aiming enhance outcomes

Language: Английский

---

Editorial: Advances in the microbiome, immunity and cancer interplay

Frontiers in Cellular and Infection Microbiology, Journal Year: 2025, Volume and Issue: 15

Published: March 31, 2025

The intricate interplay between the human microbiome and cancer immunity is a rapidly expanding field, poised to revolutionize oncological therapeutic strategies (Shi, 2024). This dynamic area of research illustrates that functions not merely as passive entity but an active participant in modulating immune responses, influencing progression diseases like colorectal (CRC) other malignancies, shaping efficacy treatments.CRC one most prevalent cancers globally, its traditional treatment protocols-which typically include surgery, chemotherapy, radiotherapy-have recently been enhanced by integration checkpoint blockers (ICBs) mainly management MSI-H/dMMR (Morgan, 2023). These advancements underscore microbiome's pivotal role responses. For instance, emerging evidence suggests specific microbiota compositions can significantly influence toxicity both radiotherapy ICBs. Fecal transplantation (FMT) being explored mitigate these adverse effects improve outcomes, highlighting novel approach CRC protocols. review manuscript Van Dingenen et al presents current preclinical clinical data on treatments, focusing interaction gut radio-and immunotherapies, examines potential benefits incorporating FMT into protocols (Frontiers | Dissecting fecal immunotherapy cancer).The notably altered patients, only tumor tissue (compared with surrounding healthy mucosa) feces, also changes their oral have evidenced. study Wang focuses assessing levels immunoglobulin SIgA, inflammatory factors, lymphocyte subsets intestinal mucosa at varying intervals post-radiotherapy, aiming determine optimal timing for surgery post-radiotherapy explore probiotics or immunomodulators through high-throughput sequencing bacterial 16s rRNA saliva recovery barrier function after radiation therapy injury ).Moreover, extends beyond cancers, such gastric (GC) breast cancer. In GC, Mendelian randomization studies pinpointed potentially affect risk, suggesting new prevention avenues (Zhang , analysis Li confirmed negative positive associations taxa GC identified several blood metabolites associated decreased risk. Notably, traits lipids phospholipids different lipoprotein particles were implicated mediators relationship certain modest mediation proportions indirect Exploring mediating risk: study).In cancer, Zeber-Lubecka indicated menopausal status may profiles, affecting disease outcomes responsiveness Breast small microbiota).Additionally, Helicobacter pylori, bacterium linked impacts extragastric conditions CRC. By altering microbial communities stomach distal large intestine, H. pylori infection modifies signatures, contributing development colon. Engelsberger complex infection, changes, immunity, well antibiotic eradication dynamics Effects microbiota, risk ).In non-small cell lung (NSCLC), Traditional Chinese Medicine (TCM) syndrome classifications profiling has opened enhancing treatments. exemplifies leveraging insights refine across various types. categorized advanced NSCLC patients based TCM syndromes treated them PD-1 inhibitors involved analyzing stool samples before using 16S flow cytometry assess nonsmall cancer: from "lung intestine stand exterior-interior relationship" theory). Results showed spleen-lung Qi deficiency Qi-Yin responded better immunotherapy. Significant shifts observed strains Clostridia, Lachnospiraceae, Lachnospirales. Patients PD-L1 expression improved including increased ratios CD3 + %, CD4 /CD8 T cells reduced suppressor subsets. findings suggest serve biomarkers providing valuable framework predicting efficacy.Wang investigated causal composition biliary tract (BTC), evaluate utility early BTC diagnosis comprehensive bidirectional analysis). Utilizing Biobank Japan (BBJ) database, which included 418 cases 159,201 controls, 18,340 participants MiBioGen consortium, employed Inverse Variance Weighting (IVW) analysis. Certain members, Streptococcaceae, Veillonellaceae, Dorea, had protective effect against BTC, while Lentisphaeria, Lachnospiraceae FCS020 Group, Victivallales reverse analysis, exposure, beneficial detrimental relationships offering developing targeted improving patient outcomes.The future likely focus integrating multi-omic (genomics, transcriptomics, metabolomics response, among others) understand host-microbiome interactions play. could lead more precise response therapies specifically modify outcomes.As we continue decipher system context it becomes increasingly clear holds significant untapped potential. manipulation regimens offers promising avenue enhance effectiveness existing overcome resistance treatment. next decade will be crucial moving concepts bench bedside, hope facing

Language: Английский

---

Designing live bacterial therapeutics for cancer

Advanced Drug Delivery Reviews, Journal Year: 2025, Volume and Issue: unknown, P. 115579 - 115579

Published: April 1, 2025

Language: Английский

---

The human microbiome: redefining cancer pathogenesis and therapy

Cancer Cell International, Journal Year: 2025, Volume and Issue: 25(1)

Published: April 28, 2025

Language: Английский

---